Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
0.3971
-0.0057 (-1.42%)
At close: Aug 7, 2026, 4:00 PM EDT
0.4251
+0.0280 (7.05%)
After-hours: Aug 7, 2026, 7:43 PM EDT
Werewolf Therapeutics Revenue
Werewolf Therapeutics had revenue of $21.00M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $21.00M.
Revenue (ttm)
$21.00M
Revenue Growth
n/a
P/S Ratio
0.92
Revenue / Employee
$1,500,000
Employees
14
Market Cap
19.30M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.89M | -18.06M | -90.55% |
| Dec 31, 2023 | 19.94M | 3.54M | 21.60% |
| Dec 31, 2022 | 16.40M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 26.55M |
| Marker Therapeutics | 3.55M |
| Daré Bioscience | 1.16M |
| Pluri | 1.08M |
| Cocrystal Pharma | 225.00K |
HOWL News
- 7 days ago - Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 7 days ago - Werewolf Therapeutics Quarterly report: Q2 2026 - Filings
- 7 days ago - Werewolf Therapeutics Earnings release: Q2 2026 - Filings
- 3 months ago - Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics Quarterly report: Q1 2026 - Filings
- 3 months ago - Werewolf Therapeutics Earnings release: Q1 2026 - Filings
- 4 months ago - Werewolf Therapeutics hires Piper Sandler to assist in strategic evaluation - TheFly
- 4 months ago - Werewolf Therapeutics reports Q4 EPS (20c), consensus (35c) - TheFly